PDGFR-β inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy.

Related Articles

PDGFR-β inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy.

Biomed Pharmacother. 2018 Mar;99:615-621

Authors: Yin L, He J, Xue J, Na F, Tong R, Wang J, Gao H, Tang F, Mo X, Deng L, Lu Y

Abstract
BACKGROUND: Pericytes are pivotal mural cells of blood vessels and play an essential role in coordinating the function of endothelial cells. Previous studies demonstrated that Endostar, a novel endostatin targeting endothelial cells, can enhance the effect of radiotherapy (RT). The present study addressed whether inhibiting pericytes could potentially improve the efficacy of combined RT and Endostar therapy.
METHODS: Platelet-derived growth factor beta-receptor inhibitor (CP673451) was chosen to inhibit pericytes and RT (12 Gy) was delivered. Lewis lung carcinoma-bearing C57BL/6 mice were randomized into 3 groups: RT, RT + Endo, and RT + Endo + CP673451. Subsequently, tumor microvessel density (MVD), pericyte coverage, tumor hypoxia, and lung metastasis were monitored at different time points following different therapies.
RESULTS: Compared to the other two groups, RT + Endo + CP673451 treatment markedly inhibited tumor growth with no improvement in the overall survival. Further analyses clarified that in comparison to RT alone, RT + Endo significantly reduced the tumor MVD, with a greater decrease noted in the RT + Endo + CP673451 group. However, additional CP673451 accentuated tumor hypoxia and enhanced the pulmonary metastasis in the combined RT and Endostar treatment.
CONCLUSIONS: Tumor growth can be further suppressed by pericyte inhibitor; however, metastases are potentially enhanced. More in-depth studies are warranted to confirm the potential benefits and risks of anti-pericyte therapy.

PMID: 29653486 [PubMed - in process]

https://ift.tt/2JKYFZY